Search
Lipocine Inc
LPCNAdd to Watchlist
2.390USD
-0.070-2.85%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.72MMarket Cap
LossP/E TTM
More Details of Lipocine Inc Company
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc Info
Ticker SymbolLPCN
Company nameLipocine Inc
IPO dateMar 21, 2014
CEOPatel (Mahesh V)
Number of employees16
Security typeOrdinary Share
Fiscal year-endMar 21
Address675 S Arapeen Dr Ste 202
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84108-1295
Phone18019947383
Websitehttps://www.lipocine.com/
Ticker SymbolLPCN
IPO dateMar 21, 2014
CEOPatel (Mahesh V)
Company Executives of Lipocine Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
FAQs
Who are the top five shareholders of Lipocine Inc?
The top five shareholders of Lipocine Inc are: Mr. John W. Higuchi
How many institutions hold shares of Lipocine Inc (LPCN)?
As of 2026Q1, 45 institutions hold shares of Lipocine Inc, with a combined market value of approximately 2.08M, accounting for 25.27% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1533872.00.